Myeloma DNA vaccine - Genvax

Drug Profile

Myeloma DNA vaccine - Genvax

Alternative Names: Myeloma vaccine (idiotypic) - Genvax

Latest Information Update: 11 May 2010

Price : $50

At a glance

  • Originator Genvax
  • Class Cancer vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Multiple myeloma

Most Recent Events

  • 11 Sep 2007 Phase-II clinical trials in Multiple myeloma in United Kingdom (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top